Glucagon-like peptide agonists and use in short bowel syndrome – what about the side effects?

Key Points

• To explore the role of GLP-2 and GLP-1 agonists in managing short bowel syndrome and their associated side effects.
• Review of current GLP-2 agonist therapies in short bowel syndrome management.
• Discussion of potential GLP-1 agonists as complementary treatments.
• Analysis of long-term studies and registry data for patient safety and treatment personalization.
• GLP-2 agonists are integral in managing short bowel syndrome.
• GLP-1 therapies may help reduce dependency on parenteral support (PS).
• Continued research is needed for optimal patient selection and safety monitoring.